BIO International Convention
-
Meet the companies attending
Seven Life and Health Sciences organizations from Northern Ireland are participating in BIO International Convention, one of the world’s largest events for biotechnology and pharma.
Northern Ireland is an excellent location for Life and Health Sciences, thanks to its unique combination of talented people, world-class research and strong links between industry, academia and clinicians, in the commercialisation of innovative research.
The region is home to more than 250 Life and Health Sciences companies who can support all aspects of your drug development cycle, from discovery through preclinical and clinical research, to commercial manufacturing and lifecycle management.
Northern Ireland continues to play a key role in solving global healthcare challenges through innovation, with businesses of all sizes focused on advancing pharmaceuticals, diagnostics, precision medicine, connected health and medical devices.
Ulster University and Queen’s University Belfast, Northern Ireland’s two major universities, provide globally competitive research expertise, along with 18 life sciences-related Centres of Excellence with over 1,000 researchers, and a proven track record in commercialising healthcare technologies.
The Northern Ireland Advantage
Following the UK’s exit from the European Union (EU), Northern Ireland is now the only region in the world with full access to both Great Britain (GB) and EU markets. It is the only place where businesses can operate free from customs declarations, rules of origin certificates and non-tariff barriers when selling to both GB and the EU. This unique position makes it easier for medical companies and medical device manufacturers based in Northern Ireland to recalibrate supply chains and to design, develop and sell products to GB and EU markets.
To find out more about Northern Ireland’s innovative capabilities visit our Life and Health Sciences sector page.
Visit us at the UK Pavilion, stand 2025.
Contact us
Connect with a member of our team
Companies attending
-
AMPLY is powering the discovery of cures for complex cancers, metabolic diseases, and infectious diseases through AI and synthetic biology. AMPLY’s platform is like ChatGPT for molecule discovery, amino acids and oligonucleotides are its building blocks, and it uses synthetic biology to turn molecule predictions into real-world candidates. AMPLY has generated thousands of novel drug candidates, advanced four unique pre-clinical drug development programmes, and secured £2.54m in grants and equity to help accelerate its drug discovery efforts.
-
ARC Regulatory is a Northern Ireland-based specialist regulatory and clinical research organisation, dedicated to supporting companies in the in vitro diagnostic and precision medicine sector.
The company’s mission is to be the preferred partner for the global precision medicine and IVD industry, supporting the development of kinder treatments and expediting the highest quality clinical research for improved patient outcomes. In delivering this mission, ARC is proud to have supported more than 50 global biomarker driven drug programmes with the world’s top targeted therapy R&D leaders.
-
CV6 Therapeutics is a clinical-stage drug development company headquartered in Belfast, Northern Ireland. The company is developing first-in-class small molecules with novel mechanisms of action that are scalable and value-driven to address global unmet medical needs in the oncology and inflammatory disease markets. CV6's first oncology drug, CV6-168, entered a first-in-human, Phase 1a trial in April of 2024 in the UK.
-
Fusion Antibodies, based in Belfast since 2001, are specialized in early-stage antibody development for therapeutics, diagnostics, and veterinary medicine. Fusion Antibodies is a CRO, working in close collaboration with its partners and offer end-to-end service from antigen design, antibody discovery, engineering, transient expression, and cell line development.
-
G&L Healthcare Advisors use subject matter expertise and decades of experience gained in every aspect of Regulatory Affairs, Quality Assurance and Clinical Development to meet the challenges faced by healthcare companies globally. The company’s comprehensive approach encompasses the entire product lifecycle, from strategic planning and regulatory submissions to post-approval activities.
Exhibiting at stand 1218
-
MediNect Ophtho specialises in tailored retinal disease research solutions for early-stage biotech companies in the preclinical therapeutics development phase. Offering proof of concept, in vivo ADME, in vitro, and mechanism of action studies, MediNect Optho provide robust readouts desired by investors and regulators. The company’s collaborative approach ensures meticulous study design and maximum study value.
-
Ulster University is Northern Ireland’s largest public university with approximately 30,000 students and 2700 staff. It is a multi-campus university with extensive campus sites in Belfast, Coleraine and Derry/Londonderry. The university delivers globally significant research with over £45 million investment in research and innovation programmes each year.